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Objective: To test the hypothesis that insulin-like growth factors-I and II (IGF-I and II) decline during late
midlife and that greater declines are related to higher fat mass and lower lean mass.
Methods: A total of 1,542 men and women in a British birth cohort study had IGF-I and II measured by
immunoassay of blood samples at age 53 and/or 60-64 years. Fat mass, android:gynoid fat ratio, and
appendicular lean mass were measured at 60-64 years using dual-energy X-ray absorptiometry (DXA).
Associations between changes in IGF-I or II and body composition outcomes were examined using con-
ditional change linear regression models.
Results: Mean IGF-I and IGF-II concentrations were lower at 60-64 than at 53 years, by 12.8% for IGF-I
and by 12.5% for IGF-II. Larger declines in either IGF-I or II were associated with higher fat mass at 60-
64 years. Although higher IGF-I at 53 years was associated with higher lean mass, there was little evi-
dence linking changes in IGF-I or II to lean mass.
Conclusions: The findings suggest that IGF-I and II concentrations decline with age, and greater
declines are associated with higher fat mass levels. These results provide some evidence for the sug-
gested roles of IGF-I and II in regulating fat mass but not lean mass in older age.
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Introduction
Insulin-like growth factors-I and II (IGF-I and II) are known to regu-
late growth in early life and are postulated to have multifaceted roles
in adult life (1,2). Evidence from multiple sources suggests that these
roles could include the regulation of body composition (fat and lean
(muscle) mass). This is important to understand given the high world-
wide prevalence of obesity and its well-documented adverse conse-
quences for health and physical functioning (3,4), and the likely inde-
pendent adverse effects of low lean mass in old age (5).
Animal studies have suggested that IGF-I may facilitate the mainte-
nance of muscle satellite cells, which aid exercise-induced muscle
hypertrophy (6,7). Small experimental studies in humans have
shown that supplementation of growth hormone (the up-stream phys-
iological regulator of IGF-I) leads to losses in fat and gains in lean
mass (8), and Laron syndrome (genetic insensitivity to growth hor-
mone) is characterized by high fat mass levels which are reversed
by IGF-I therapy (9). Experimental studies have also shown that
obese people have blunted IGF-I generation in response to growth
hormone stimulation, suggesting bi-directionality in the association
between IGF-I and fat mass (8).
Although IGF-II concentrations in adults are three- to fivefold
higher than IGF-I concentrations (10), its roles are less well under-
stood (11), particularly because IGF-II is not expressed postnatally
in mouse models unlike in humans. Genetic and epigenetic studies
have suggested that IGF-II may regulate fat and lean mass: IGF-II
genetic variants have been associated with body weight (12) and
lean mass (13), and epigenetic differences in IGF-II have been asso-
ciated with skinfold thickness (14).
Observational studies can contribute to understanding how IGF-I
and II concentrations change with age, and how these changes
impact on body composition. Limited evidence from cross-
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sectional studies shows that IGF-I concentrations are lower in old
age (15-18), suggesting that the decline in IGF-I may be impli-
cated in age-related gains in fat and losses in lean mass (19).
IGF-I has been cross-sectionally inversely associated with body
mass index (BMI) or body weight (20), with some studies report-
ing that those with lowest or highest BMI have lower IGF-I
(21,22). However, such findings do not elucidate whether IGF-I is
associated with fat and/or lean mass. Cross-sectional studies of
body composition measures have yielded equivocal findings with
IGF-I, and few have examined associations with IGF-II (23),
leading to uncertainty in the roles of IGF-I and II in regulating
body composition.
The objectives of this study were to examine the relevance of age-
related changes in circulating IGF-I and II concentrations during
late midlife to fat and lean body mass in a British birth cohort
study. The strengths of this study are the repeat measures of IGF-I
and II, 7-11 years apart, a large sample of both sexes, and meas-
ures of body composition obtained in early old age using dual-
energy X-ray absorptiometry (DXA). We hypothesized that larger
decline in IGF-I and II would be associated with higher fat and
lower lean mass.
Methods
Study sample
The MRC National Survey of Health and Development (NSHD) is a
socially stratified sample of 5,362 singleton births that took place in
1 week of March 1946 in mainland Britain, with regular follow-up
across life. Between 2006 and 2010 (at 60-64 years), 2,856 eligible
study members (those known to be alive and with a known address
in England, Scotland, or Wales) were invited for an assessment at
one of six clinical research facilities (CRFs) or to be visited by a
research nurse at home. Invitations were not sent to those who had
died (n 5 778), who were living abroad (n 5 570), had previously
withdrawn from the study (n 5 594) or who had been lost to
follow-up (n 5 564). Of those invited, 2,229 (78%) were assessed:
1,690 (59.2%) attended a CRF and the remaining 539 were seen at
home (24).
Body composition measurement
During the visits to the CRF, measures of body composition were
obtained in the supine position using a QDR 4500 Discovery
DXA scanner (Hologic, Bedford, MA) with APEX 3.1 analysis
software. From these scans, measures of fat (whole body, abdomi-
nal (android) and hips (gynoid)) and appendicular (limb) lean
mass were obtained and converted into kilograms. The ratio of
android:gynoid fat mass was derived (higher values indicating
greater fat distribution in the abdomen than hips) and multiplied
by 100. Lean mass was defined as body mass excluding fat mass
and bone mineral content (BMC), and in all measures data from
the head were excluded due to the high proportion of BMC known
to affect the accuracy of soft-tissue measures. Measures selected
for analysis were: whole body fat mass (kg), android:gynoid ratio
(multiplied by 100), and appendicular lean mass (kg). Data on
these outcomes were available for 1,558 participants, with missing
data in 132 participants largely due to the presence of high-
density artefacts (e.g., joint replacements). The study received
multicenter research ethics committee approval, and informed con-
sent was given by participants.
Measurement of IGFs
At 53 years, non-fasting venous blood samples were taken in tubes
containing ethylenediaminetetraacetic acid (EDTA) during home
visits by research nurses. These were posted overnight to a labora-
tory where plasma was extracted and frozen at 280C. At 60-64
years, overnight fasting venous blood samples were obtained in
tubes containing liquid citrate. These were then taken immediately
to a laboratory in each CRF (clinic visit) or posted overnight to a
CRF (home visit) and plasma extracted before being frozen at
280C. IGF-1, IGF-II, and IGFBP-3 were obtained by radioimmu-
noassay using standardized protocols in the same laboratory; in all
except 200 pilot samples, assays were conducted in duplicate and
mean values used in analyses. Intra-assay coefficients of variation
were 3.4% for IGF-I, 2.8% for IGF-II, and 3.9% for IGFBP-3.
Assays were repeated where intra-assay coefficients of variation
exceeded 15%. Inter-assay coefficients of variation were 13.7%
(IGF-I), 7.4% (IGF-II), and 11.7% (IGFBP-3); to minimize inter-
assay variability, in most instances the same laboratory technician
assayed each analyte.
Analytical strategy
As taller individuals tend to have more fat and lean mass, height-
adjusted indices were created by dividing fat and appendicular lean
mass (kg) by height(m)X, where X was calculated so that the result-
ing index was not correlated with height (X 5 1.2 for fat and 2 for
lean mass) (25).
First, the associations of IGF-I and IGF-II at 53 and 60-64 years
with fat and lean mass at 60-64 years were examined using linear
regression. To aid the interpretation of model coefficients, each IGF
measure was converted into sex-specific z-scores, and outcomes
were log transformed and multiplied by 100; regression coefficients
therefore show the mean percentage difference in outcome per 1
standard deviation increase in IGF. Findings did not differ when
IGF measures were modeled as either z-scores or as absolute values.
Second, associations between change in IGF-I and II and fat and
lean mass were examined using conditional change models—calcu-
lated change in IGF was included in models that also included the
baseline IGF concentration at 53 years. Change scores were con-
verted to sex-specific z-scores to aid interpretation of model coeffi-
cients. Given previous evidence for sex differences in associations
(26), sex interaction terms were tested—where significant interac-
tions were found (P < 0.05), models were conducted separately in
each sex; otherwise models were adjusted for sex.
Associations with lean mass could be confounded by fat mass, as
changes in fat mass typically lead to adaptive changes in lean mass
(27). As such, models using lean mass as an outcome were addition-
ally adjusted for fat mass. The change models were also additionally
adjusted for further potential confounders at age 53 identified a-pri-
ori: household occupational class, smoking status (categorized as
non-smoker or light (1-10), moderate (11-20), or heavy smoker
(>20 cigarettes per day)) and menopausal status (categorized as pre-
, peri-, or post-menopausal, hysterectomy with or without hormone
replacement therapy, other hormone replacement therapy user, or
other reason for menstrual period cessation) (28). Complete case
analyses were performed to examine IGF and body composition
associations: 594 men and 644 women had complete body composi-
tion and IGF data at both ages; of these, 588 men and 623 women
also had complete data for all potential confounders.
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Additional and sensitivity analyses
To examine the possibility of reverse or bi-directionality, change
models with fat mass were repeated with additional adjustment
for BMI at 53 (as DXA measures were not available at 53), and
analyses were conducted in which BMI (or change in BMI) was
the exposure, and IGF-I or II the outcome. As IGF-I and physical
activity may influence muscle mass synergistically (7), we also
examined whether physical activity modified the association
between IGF-I and lean mass by including an interaction term
with leisure time physical activity at both 53 and 60-64 years
(categorized as no participation, 1-4 episodes, and 5 episodes in
the previous 4 weeks). To examine the extent to which associa-
tions between IGF and body composition were driven by height,
we also conducted analyses without adjustment for height. To
examine whether associations between IGFs and body composition
outcomes were non-linear, we examined plots of the data and
compared linear models with models additionally including quad-
ratic terms for IGFs. We also examined whether associations
between changes in IGFs and body composition were non-linear,
by repeating analyses using change score variables converted into
quartiles. These categorical models were then compared with lin-
ear models using likelihood ratio tests.
Results
Descriptive analyses
At both 53 and 60-64 years, men had higher IGF-I but lower IGF-II
concentrations than women (Table 1). In both sexes, mean IGF-I
and II concentrations were lower at 60-64 than 53 years—by 12.8%
for IGF-I and 12.5% for IGF-II; larger declines were seen in
IGFBP3 and therefore the mean IGF-I:IGFBP3 ratio was higher at
60-64 years. Most, but not all, participants showed a decline in IGF-
I (66%) and IGF-II (65%) concentrations (Supporting Information
Figure 1). Women had greater whole body fat and less lean mass
than men, and a lower android:gynoid ratio.
IGF-I showed moderately positive correlations with IGF-II and
IGFBP-3 at both 53 and 60-64 years (Supporting Information
Table 1).
Associations between IGFs and fat mass
IGF-I at 53 (in women) and 60-64 years (both sexes) was inversely
associated with fat mass at 60-64 (Table 2). Conversely, IGF-II at
53 years was positively associated with fat mass, while IGF-II at
60-64 years was inversely associated with fat mass. Associations
between IGF-I or II with BMI and android:gynoid ratio at 60-64
years was generally similar to those with fat mass index (Supporting
Information Table 2).
Greater decline in IGF-I between 53 to 60-64 years was weakly
and non-significantly associated with higher fat mass, and higher
android:gynoid ratio at 60-64 years (Table 2). Greater decline in
IGF-II was associated with higher fat mass, but not android:
gynoid ratio. These associations were similar albeit partly attenu-
ated when additional adjustment was made for potential con-
founders (Table 2). Associations of IGFBP-3 and IGF-I: IGFBP-
3 with these outcomes are shown in Supporting Information
Table 3.
TABLE 1 Summary of body composition and IGF concentrations by sex
Men, mean (SD or IQR) Women, mean (SD or IQR) Pa
Body composition at 60-64 y N 5 746 N 5 812
Fat mass index (kg m22) 12.02 (3.63) 16.20 (4.97) <0.001
Android fat mass (kg) 2.47 (0.96) 2.34 (0.98) 0.02
Gynoid fat mass (kg) 3.73 (1.00) 5.11 (1.41) <0.001
Android:gynoid ratio 65.16 (15.50) 44.93 (12.04) <0.001
Appendicular lean mass index (kg m22) 8.02 (0.95) 6.19 (0.87) <0.001
IGF concentration, age N 5 744 N 5 798
IGF-I (ng ml21), 53 y 211.2 (66.3) 194.6 (67.9) <0.001
IGF-I (ng ml21), 60-64y 185.7 (59.9) 168.2 (58.6) <0.001
D IGF-I (ng ml21) 225.5 (260, 14) 226.4 (267, 224) 0.80
IGF-II (ng ml21), 53 y 747.7 (254.2) 796.6 (247.6) <0.001
IGF-II (ng ml21), 60-64 y 647.0 (308.0) 703.0 (291.5) <0.001
D IGF-II (ng ml21) 2100.6 (2321, 99) 293.5 (2358, 115) 0.70
IGFBP-3 (ng ml21), 53 y 4781.7 (1083.2) 4835.9 (1122.5) 0.30
IGFBP-3 (ng ml21), 60-64 y 3219.5 (832.4) 3457.7 (831.5) <0.001
D IGFBP-3 (ng ml21) 21562.2 (22244, 2881) 21378.1 (22142, 2592) <0.001
IGF-I:IGFBP-3, 53 y 4.6 (1.7) 4.2 (1.9) <0.001
IGF-I:IGFBP-3, 60-64 y 6.0 (2.5) 5.0 (1.5) <0.001
D IGF-I:IGFBP-3 1.4 (0.17, 2.6) 0.8 (20.35, 1.9) <0.001
aComparison between sexes using t tests; IGF-I/IGFBP-3 ratio was multiplied by 100; analyses restricted to participants with valid data for all body composition outcomes
or all hormone measures at both ages.
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Associations between IGFs and lean mass
After adjustment for fat mass, IGF-I at 53 was positively associated
with appendicular lean mass at 60-64 years, while associations
between IGF-I at 60-64 years and lean mass were weak and not sig-
nificant (Table 3). After adjustment for fat mass, IGF-II was not
associated with lean mass in either sex, and nor were changes in
IGF-I or II.
Additional and sensitivity analyses
Associations between declines in IGF-I and II and fat mass were
similar after additional adjustment for BMI at 53 years (P 5 0.04
for IGF-I and P 5 0.13 for IGF-II; Supporting Information Table
4). Greater gain in BMI from 53 to 60-64 years (modeled as the
exposure) was weakly associated with lower IGF-I at 60-64 years
(modeled as the outcome), but not with IGF-II at 60-64 years (Sup-
porting Information Table 5).
There was no evidence for effect modification by physical activity
in the association between IGF-I and lean mass (P values for inter-
action term>0.4 at both 53 and 60-64 years). For all outcomes, con-
clusions did not differ when not adjusting for adult height. There
was no substantive evidence for deviation from linearity with IGF at
TABLE 2 Mean percentage differences in fat mass and android:gynoid ratio (95% CI) at age 60-64 years per 1 standard
deviation increase in IGF-I and IGF-II at 53 and 60-64 years
Fat mass index Android:gynoid fat mass ratio
N b (95% CI) P
P (sex
interaction) b (95% CI) P
P (sex
interaction)
IGF-I at 53y Men 627 0.38 (22.04, 2.79) 0.76 <0.01 20.30 (21.74, 1.13) 0.68 0.16
Women 704 24.06 (26.26, 21.85) <0.001
IGF-I at 60-64 y 1,434 22.12 (23.71, 20.52) <0.01 0.94 20.73 (22.11, 0.66) 0.30 0.15
D IGF-I 1,211 21.86 (24.02, 0.30) 0.09 0.61 21.33 (23.23, 0.57) 0.17 0.24
D IGF-I, adjusted* 1,211 21.56 (23.71, 0.59) 0.16 0.51 20.96 (22.86, 0.94) 0.32 0.19
IGF-II at 53y 1,331 3.24 (1.61, 4.86) <0.001 0.26 2.71 (1.28, 4.14) <0.001 0.30
IGF-II at 60-64 y 1,434 21.55 (23.15, 0.05) 0.06 0.09 0.76 (20.63, 2.14) 0.28 0.55
D IGF-II 1,211 22.01 (24.05, 0.03) 0.05 0.10 0.27 (21.53, 2.06) 0.77 0.26
D IGF-II, adjusteda 1,211 21.94 (23.96, 0.08) 0.06 0.11 0.26 (21.53, 2.04) 0.78 0.27
Note: Sex-specific findings shown where P (sex interaction)<0.05; otherwise, models are adjusted for sex. D change between 53 and 60-64 years—analyses adjusted for
hormone concentration at 53 years.
aAdjusted for highest household occupational class, smoking, and menopausal status at age 53 years.
TABLE 3 Mean percentage differences in appendicular lean mass (95% CI) at age 60-64 years per 1 standard deviation
increase in IGF-I and IGF-II at 53 and 60-64 years
Appendicular lean mass index, unadjusted
Appendicular lean mass index,
adjusted for fat mass index
N b (95% CI) P
P (sex
interaction) b (95% CI) P
P (sex
interaction)
IGF-I at 53 y Men 627 0.97 (0.05, 1.89) 0.04 <0.01 0.65 (0.10, 1.21) 0.02 0.19
Women 704 21.02 (22.03, 20.01) 0.05
IGF-I at 60-64y 1,434 20.39 (21.05, 0.28) 0.25 0.86 0.26 (20.28, 0.80) 0.34 0.87
D IGF-I 1,211 20.75 (21.66, 0.16) 0.11 0.62 20.25 (20.98, 0.49) 0.51 0.65
D IGF-I, adjusteda 1,211 20.69 (21.60, 0.22) 0.14 0.70 20.28 (21.01, 0.46) 0.46 0.83
IGF-II at 53 y 1,331 0.95 (0.26, 1.63) <0.01 0.33 0.23 (20.33, 0.79) 0.41 0.69
IGF-II at 60-64 y 1,434 20.34 (21.01, 0.32) 0.31 0.84 0.10 (20.44, 0.64) 0.72 0.33
D IGF-II 1,211 20.43 (21.29, 0.43) 0.33 0.56 0.11 (20.58, 0.81) 0.75 0.53
D IGF-II, adjusteda 1,211 20.33 (21.19, 0.53) 0.45 0.67 0.19 (20.50, 0.89) 0.59 0.42
Note: Sex-specific findings shown where P (sex interaction) < 0.05; otherwise, models are adjusted for sex. D change between 53 and 60-64 years—analyses adjusted
for hormone concentration at 53 years.
aAdjusted for highest household occupational class, smoking, and menopausal status at age 53 years.
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each age, nor with change in IGF-I or II (P values from likelihood
ratio tests >0.35 in all cases).
Discussion
Longitudinal data from a large British birth cohort study showed
evidence for declines in both IGF-I and II concentrations during late
midlife (53 to 60-64 years), which were associated with higher fat
mass at 60-64 years. While IGF-I at 53 years was positively associ-
ated with lean mass at 60-64 years, there was little evidence that
changes in IGF-I and II, per se, were associated with lean mass in
either sex.
Our findings add substantially to previous cross-sectional evidence
for lower IGF-I concentrations in older versus younger adults (15-
18), and one small longitudinal study which reported a decline in
IGF-I during mid-late life among participants enrolled in a colono-
scopy study (N 5 143) (29). The results also add to previous cross-
sectional studies conducted on smaller samples which reported
equivocal findings on the relationship between IGF-I and body com-
position. For example, in a cross-sectional study of Dutch older
adults, IGF-I was inversely associated with BMI, and weakly inver-
sely associated with fat and lean mass in men, but not women (26).
In other cross-sectional studies of adults, IGF-I was inversely (30),
positively (31), or not associated with lean mass (32,33); and inver-
sely (32), or not associated with fat mass (30,31,33). Previous stud-
ies have also found evidence that the IGF-I and BMI cross-sectional
association is non-linear, with those with highest or lowest BMI
having lower IGF-I (21,22). However, there was little evidence for
this in our models using either fat mass or BMI as the outcome
(Supporting Information Figures 2 and 3) with mean IGF-I levels
declining with increasing quintiles of body mass or fat mass index.
Taken together, these results provide some evidence to support the
roles of IGF-I and II in the regulation of fat mass. The weak mag-
nitude of associations (and non-significant P values found in some
cases) may be explained by the contribution of other influences on
fat mass which we were unable to control for, and by imprecision
in the extent to which a single measure of circulating IGF reflects
long-term concentrations (e.g., due to day-do-day variation) and
bioactivity. The presence of feedback loops may also weaken
observed associations. For example, while increases in IGF-I may
reduce fat mass levels, higher IGF-I would also down-regulate
growth hormone secretion, which in turn would result in lower
IGF-I. Associations between IGF-I and fat mass could also be
explained in part by reverse causation or bi-directionality, as obese
subjects are known to have relative growth hormone insensitivity
compared with nonobese subjects (8). Although associations
between change in IGF-I and fat mass were not substantively atte-
nuated after adjustment for BMI at 53 year, greater gains in BMI
were (weakly) associated with lower IGF-I. Finally, IGF-I could
simply be a surrogate marker for the direct actions of growth hor-
mone on mature adipocytes (8).
Lack of association, or weak association, between changes in total
serum IGF concentrations and lean mass could suggest that IGF-I
or II are not important regulators of adult lean mass. This is con-
trary to reported findings from some studies which reported higher
adult protein intake, a likely determinant of muscle mass, associ-
ated with higher IGF-I concentrations (34). However, our findings
do not preclude the importance of IGF-I and II in regulating muscle
growth in early life, nor local IGF actions on adult lean mass—
some experimental studies have shown that exercise increases local
(muscle) IGF-I but not total serum IGF-I concentrations (35).
Unlike total IGF-I concentrations, mean IGF-I:IGFBP-3 ratio
increased between 53 to 60-64 years due to the relatively larger
decline in IGFBP-3. IGFBP-3 is one of six binding proteins that
carry IGF-I in circulation. If IGFBP-3 acts as an inert carrier pro-
tein, then the IGF-I:IGFBP-3 ratio could better indicate biologically
available IGF-I than total IGF-I concentration. However, evidence
for direct biological actions of IGFBP-3 suggests otherwise—
IGFBP-3 and other IGF binding proteins have their own cellular
actions which include enhancing IGF activity (36). As such, associa-
tions between IGF-I:IGFBP-3 ratio and outcomes should be inter-
preted with caution. However, directly measured “free” and/or bio-
active IGF-I or II may decline with age, and its decline may relate
more closely to body composition outcomes than total measures.
This warrants investigation in future studies although at present
there are no universally accepted standardized methods for meas-
uring “free” or bioactive concentrations of IGFs and the interpreta-
tion of these measurements is still subject to discussion.
It is unclear what up-stream factors cause the observed age-related
declines in IGF-I and II. IGF-I has been hypothesized to be a bio-
marker which mediates the roles of physical activity (and other fac-
tors) on body composition and health outcomes (37). However, it
remains unclear if this is the case. While studies have consistently
found greater milk consumption in early life is associated with lower
IGF-I concentration in adulthood (38), studies examining the adult-
hood determinants of IGF have yielded equivocal findings [e.g., in
relation to reported energy intake and physical activity level (20)].
These determinants are being investigated in the NSHD and warrant
investigation in other cohorts.
Strengths of this study include the accurate measures of fat and lean
mass in both sexes, and repeat measures of both IGF-I and II. The
single DXA measures obtained at 60-64 years however precluded
the analysis of how changes in IGF relate to change in fat and lean
mass. Intra-assay coefficients of variation were low, which limited
measurement error; while inter-assay coefficient variations were
larger, the ranking of participant IGF values was unlikely to be sub-
stantially affected as assay results were calibrated using control
samples.
Limitations of study include loss to follow-up, which despite the
large sample size reduced statistical power and may have intro-
duced bias (if the exposure-outcome association differed in the
sample lost to follow-up). Methodological differences in blood
sample collection at 53 and 60-64 years could have affected the
results obtained—the longer storage time of samples collected at
53 years could have resulted in IGF degradation, which would
attenuate the declines in IGF-I and II observed with age. Con-
versely, the liquid citrate used at 60-64 years may have reduced
IGF concentrations. Blood samples at 53 years were obtained dur-
ing home visits, which likely resulted in a longer time to freezing
compared with the 60-64 year samples. However, a methodological
study suggested that time to freezing did not substantially affect
IGF-I concentrations (39), and IGF-I and II concentrations at 53
years did not differ by time of day at sampling (morning, after-
noon, or evening; P > 0.3 in all cases). More than two time points
Obesity Changes in IGF-I and II Related to Body Composition Bann et al.
696 Obesity | VOLUME 23 | NUMBER 3 | MARCH 2015 www.obesityjournal.org
of measurement would provide more informative data on the tra-
jectories of change in IGF concentrations with age.
Findings from the present study add substantially to our under-
standing of the age-related changes in IGF-I and II, and their con-
sequences for body composition. However, the implications of
these findings are not straightforward. Lowering fat mass levels by
pharmacological supplementation of IGF (or growth hormone) is
likely to be unwarranted given expected increases in cancer risk
(40). Rather, behavioral or early life interventions acting on the up-
stream determinants of IGF-I and II may potentially lessen their
decline with age in later mid-life, and in turn could limit the accu-
mulation of fat mass during this period of ageing.
Conclusion
Using longitudinal data from a British birth cohort study, evidence
was found for declines in IGF-I and II concentrations from 53 to
60-64 years, and greater declines were weakly associated with
higher fat mass at 60-64 years. There was little evidence that
changes in IGF-I and II were associated with lean mass.O
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